Recently diagnosed with HIV? Click here

New NRTI no more

Positive Living article • Adrian Ogier • 11 June 2010

The shelving of apricitabine does not come as a surprise in the competitive HIV sector, in which market growth is increasingly being driven by fixed-dose combinations (FDCs) such as Atripla which offer improved patient convenience.

Furthermore, apricitabine’s twice-daily administration impedes its potential for combination with other antiretroviralA medication or other substance which is active against retroviruses such as HIV. drugs and limits its scope for use in FDCs.

This is reflected in the fact that there are currently no other NRTIs in late-stage development for HIV.

  • Delicious
  • Digg
  • StumbleUpon
  • Reddit
  • Facebook
  • Google
  • Yahoo
  • Technorati
Text size: font smallerfont normalfont larger print-friendly version of this pagePDF version of this pageemail this page to a friend

From Positive Living

This article was first published in the June 2010 issue of Positive Living — more than one year ago.

While the content of this was checked for accuracy at the time of publication, NAPWA recommends checking to determine whether the information is the most up-to-date available, especially when making decisions which may affect your health.

This article may contain medical information. NAPWA makes every reasonable effort to ensure the information on this website is accurate, reliable and up-to-date, including obtaining technical reviews by medically-qualified reviewers, however the authors of information on this website are not qualified to give medical advice, except where explicitly stated.

The content of this website is intended to support, not replace, the relationship between people living with HIV/AIDS and their medical advisers, and is not intended as a substitute for medical advice.

HIV Clinical Trials update

Recently updated entries from the NAPWA Clinical Trials database.

more